Neumora Therapeutics is trading 5.18% down in after-hours trading at $0.69 after no clear company-specific catalyst was identified for September 21, 2026.

  • Recent coverage cited favorable NMRA-215 toxicology results and planned clinical advancement, but those announcements predated the move.
  • The decline diverged from a broadly positive session, with the Nasdaq Composite up 2.42%, leaving the immediate catalyst unclear.